The solution lies in flexibility. Sites need to be able to work in whatever formats make sense for them, whether that’s a ...

At OCT Nordics, Karin Nordbladh recounted Alligator Bioscience’s experience of implementing the FDA’s dose optimisation ...

This ASCO State of Cancer Care in America Special Report documents ASCO's position on the essential role clinical trials play in improving cancer care and patient outcomes, current challenges and ...

Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated ...

ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States The following represents disclosure information provided by authors of this manuscript.

Big pharmas unveil ADC and radiopharmaceutical phase 3 wins at ESMO Big pharmas report pivotal phase 3 wins for ADCs and ...

Fenbendazole has gotten a lot of attention in recent years. It is a deworming medicine that treats infections caused by ...

Akeso CEO Xia gained experience in the US before launching her own biotech company back home in China. Now its ...

In October 2025, a partnership between Biokin-a rising star in China's innovative pharmaceutical sector-and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is ...

Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...

Investing.com -- Ipsen SA shares climbed more than 6% on Wednesday after the French biopharmaceutical company lifted its 2025 outlook and posted third-quarter sales that beat forecasts, driven by ...

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...